Trellus Health (AIM:TRLS) has signed a renewal of its Licensing Agreement with Pfizer Inc to continue licensing Trellus’s patient support educational content for inclusion in Pfizer’s inflammatory bowel disease (IBD) digital application.
The continued placement inside a pharmaceutical-grade digital app validates its resilience-based content and methodology, Trellus said.
Chief executive and co-founder Dr. Marla Dubinsky framed the renewal as part of a wider commercial push.
"We are excited to extend this agreement with Pfizer, which underscores both the continued engagement of their users with our content on the platform and the value of our resilience-driven approach and methodology. Alongside our recent Gastro Health Master Services Agreement, the extension of our collaboration with Johnson & Johnson, and the continued roll-out of TrialSet™ across clinical trials, this renewal further supports the applicability of our platform across the pharmaceutical lifecycle. We remain focused on advancing commercial discussions and converting pipeline opportunities into revenue," Dr. Marla Dubinsky said.
Trellus noted that it has reduced monthly cash burn to an average of c.$300k as of March 2026. With the Pfizer renewal and a loan from Laurie Keefer, Ph.D., the company’s scientific co-founder, Trellus expects its cash runway to extend into May 2026.
The board remains supportive of the company’s commercial strategy and is engaged in ongoing discussions about a range of potential funding options to further extend the cash runway, the company said.
